Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Foveal center-involving macular edema secondary to BRVO diagnosed within 12 months before study enrollment~2. ETDRS chart BCVA: 63 to 77 letters (20/32 to 20/50 Snellen equivalent)~3. CFT \>= 300 um (mean of measurements obtained at screening and Day 0)~4. Signed consent informed~5. male or female, age ≥18 years old~Exclusion Criteria:~1. Prior episode of RVO: Past history of RVO in the study eye diagnosed before 1 year of study enrollment.~2. BCVA improvement \>10 letters between screening and Day 0~3. History of other ocular diseases (e.g. diabetic retinopathy, age-related macular degeneration)~4. Laser treatment within 3 months before baseline~5. Intraocular corticosteroid use within 3 months before baseline~6. Anti-vascular endothelial growth factor (VEGF) treatment in the study or fellow eye within 3 months before baseline~7. Intraocular surgery other than cataract surgery, Cataract surgery within 6 months before baseline~8. Stroke or myocardial infarction ≤3 months before baseline~9. Pregnancy or plan to have baby in female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab group (Type: EXPERIMENTAL): Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
- Standard of care group (Type: SHAM_COMPARATOR): Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).